These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 6751065)

  • 21. The beneficial effects of verapamil in chronic atrial fibrillation.
    Klein HO; Pauzner H; Di Segni E; David D; Kaplinsky E
    Arch Intern Med; 1979 Jul; 139(7):747-9. PubMed ID: 454060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation.
    Pomfret SM; Beasley CR; Challenor V; Holgate ST
    Clin Sci (Lond); 1988 Apr; 74(4):351-7. PubMed ID: 3281786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Limitations of serum digitalis levels.
    Noble RJ; Rothbaum DA; Watanabe AM; Besch HR; Fisch C
    Cardiovasc Clin; 1974; 6(1):299-311. PubMed ID: 4611615
    [No Abstract]   [Full Text] [Related]  

  • 24. Atrial fibrillation in the Wolff-Parkinson-White syndrome: effects of verapamil and procainamide.
    Laufer N; Crevey B
    Ariz Med; 1985 Mar; 42(3):150-3. PubMed ID: 3994532
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of arrhythmias with "calcium antagonists".
    Zipes DP; Gilmour RF
    Angiology; 1982 Aug; 33(8):540-54. PubMed ID: 6287890
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation.
    Matsuda M; Matsuda Y; Yamagishi T; Takahashi T; Haraguchi M; Tada T; Kusukawa R
    Cardiovasc Res; 1991 Jun; 25(6):453-7. PubMed ID: 1889058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection.
    Auricchio A
    Am Heart J; 1992 Oct; 124(4):932-7. PubMed ID: 1529904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of aminophylline on electrophysiological characteristics of the accessory pathway in patients with Wolff-Parkinson-White syndrome].
    Ostapiuk M; Telichowski C; Petruk J; Molenda W; Banasiak W
    Kardiol Pol; 1988; 31(3):173-9. PubMed ID: 3221612
    [No Abstract]   [Full Text] [Related]  

  • 29. Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation.
    Strasberg B; Sagie A; Rechavia E; Katz A; Ovsyscher IA; Sclarovsky S; Agmon J
    Cardiovasc Drugs Ther; 1989 Jan; 2(6):801-6. PubMed ID: 2488095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Wolff-Parkinson-White syndrome and verapamil: apropos of a case of ventricular fibrillation].
    Michel B; Goy JJ; Kappenberger L
    Schweiz Med Wochenschr; 1989 May; 119(19):630-4. PubMed ID: 2740877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of verapamil on the electrophysiologic properties of the accessory pathway in patients with the Wolff-Parkinson-White syndrome.
    Harper RW; Whitford E; Middlebrook K; Federman J; Anderson S; Pitt A
    Am J Cardiol; 1982 Dec; 50(6):1323-30. PubMed ID: 7148709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Verapamil in the study and treatment of supraventricular tachycardias, with special reference to pre-excitation].
    Krikler DM
    Minerva Med; 1975 May; 66(39):1914-22. PubMed ID: 236526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.
    Lewis RV; McMurray J; McDevitt DG
    J Cardiovasc Pharmacol; 1989 Jan; 13(1):1-6. PubMed ID: 2468920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of verapamil and digoxin in the treatment of atrial fibrillation.
    Lewis R; Lakhani M; Moreland TA; McDevitt DG
    Eur Heart J; 1987 Feb; 8(2):148-53. PubMed ID: 3552680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of digitalis in the future.
    Poole-Wilson PA
    Br J Clin Pharmacol; 1984; 18 Suppl 2(Suppl 2):151S-156S. PubMed ID: 6532481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Supraventricular tachycardias.
    Wu D
    JAMA; 1983 Jun; 249(24):3357-60. PubMed ID: 6854872
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of rapid ventricular rate in acute atrial fibrillation.
    Shettigar UR
    Int J Clin Pharmacol Ther; 1994 May; 32(5):240-5. PubMed ID: 7921518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Digitalis therapy for congestive heart failure: is the jury still out?
    Salem DN; Berner S; Eichorn EJ; Sherman L; Konstam MA
    Pharmacotherapy; 1988; 8(6):319-23. PubMed ID: 3065745
    [No Abstract]   [Full Text] [Related]  

  • 39. Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis.
    Panidis IP; Morganroth J; Baessler C
    Am J Cardiol; 1983 Dec; 52(10):1197-201. PubMed ID: 6359848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Digitalis in heart failure! Still applicable?
    Hoppe UC; Erdmann E
    Z Kardiol; 2005 May; 94(5):307-11. PubMed ID: 15868358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.